Why isn't a supplier's own COA enough?

A manufacturer's COA is a starting point, not a verdict. We re-run identity and purity at an independent lab, not the one the manufacturer uses, because self-reported numbers can't be audited on their own. Only independent retesting confirms the label matches the vial.

What does "99% purity" actually tell you?

Less than it seems, on its own. A 99% purity figure is only meaningful if the remaining 1% is characterized. If that fraction is an unidentified compound the supplier can't account for, the number is close to meaningless. The impurity profile matters as much as the headline percentage.

Why is the cheapest peptide source usually the wrong one?

The cost of independent testing across multiple lots is real, and suppliers who skip it can price lower. Spot-buying the cheapest source means inheriting that skipped verification. Consistent label-to-vial accuracy costs money to guarantee.

How many tests does a manufacturer have to pass?

We require two independent test rounds across two separate lots before a manufacturer joins our active list, verifying that quality is repeatable and not a one-batch fluke.

How We Vet a New Peptide Manufacturer: Our COA & Testing Standard

We get asked often what separates a research peptide worth buying from one that isn't. Most of the answer happens long before a vial ships, in manufacturer vetting. This is the actual process a new supplier goes through before anything they make reaches our shelves. We are publishing it because, in a category with uneven quality, the standard itself is the product.

This is written for research and educational purposes. Our compounds are supplied for academic and pre-clinical study and are not approved for human use.

Step 1: Documentation — a real COA, tied to a real lot

When a new supplier comes across our desk, we start with paperwork. Specifically, a certificate of analysis (COA) tied to a specific production lot, not a generic spec sheet pulled from a catalog and reused across every batch. A COA that isn't lot-specific tells you nothing about the vial in your hand.

A COA worth trusting reports, at minimum:

What a valid COA must report

Element	What it shows	Why it matters
Lot / batch number	Ties the document to a specific production run	A generic spec sheet is not a COA
Mass by HPLC	Quantifies the main compound and separates impurities	The core purity measurement
Identity by mass spectrometry	Confirms the molecule is what the label says	Purity is meaningless if the identity is wrong
Measured purity (%)	The headline number, as tested	Must be a measurement, not a claim
Impurity profile	What the non-target fraction actually is	A characterized 1% is very different from an unknown 1%

The COA should report mass by HPLC, identity by mass spectrometry, and a measured purity figure ^[1]: measurements, not claims. If the documentation is vague, unsigned, or not tied to a lot, the review usually ends here.

Step 2: Independent third-party retesting

If the paperwork holds up, we don't take it at face value. We order an unmarked sample and send it to an independent lab, not the one the manufacturer uses. We re-run identity and purity ourselves.

This is the step most spot-buyers skip, and it is the one that matters most. A manufacturer's own COA is a starting point, not a verdict; self-reported numbers can't be audited on their own. Independent retesting is what confirms the label matches the vial, and it occasionally doesn't.

Step 3: Read the impurity profile, not just the percentage

A purity percentage is only as good as what sits in the remainder. A 99% purity number is close to meaningless if the remaining 1% is an unknown compound the supplier can't account for. So we look at the impurity profile directly: what the non-target fraction is, whether it is characterized, and whether it is consistent with the synthesis route. ^[2] A characterized 1% of a known, benign process-related impurity is a very different thing from an unidentified 1% no one can name.

Step 4: Two lots, not one

A single clean result can be luck. Consistency is the actual signal. So we require two independent test rounds across two separate lots before a manufacturer is added to our active list. Passing once proves a batch; passing twice, across different production runs, starts to prove a process. Quality that isn't repeatable isn't quality: it is a coincidence we decline to build a supply chain on.

Why the cheapest source is almost never the right one

All of this, independent labs, multiple lots, impurity-profile review, costs money and time. Suppliers who skip it can price lower, and spot-buying the cheapest source means silently inheriting every verification step they cut. The price gap between a rigorously tested peptide and a bargain one is largely the cost of the testing itself. We think that is the right thing to pay for, because the alternative is not knowing what is in the vial.

It is slower and more expensive than spot buying. It is also the only method we have found that reliably keeps what is on the label consistent with what is in the vial, which, for research material, is the entire job.

For a long time I bought the way most people do: on price and whatever purity number was printed on the PDF. It felt rigorous enough: there was a certificate, the number was high, the vial arrived.

Then a lot that shipped with a "99% pure" certificate failed an independent retest I ran myself. Not marginally. The identity didn't even cleanly match what the label claimed. Every experiment I'd run on the previous batch from that supplier was suddenly suspect, because I no longer knew what had actually been in the vial.

Now the only two things I care about are a batch-matched COA and a supplier whose material survives an independent lab that isn't theirs. It costs more per vial, and I've made my peace with that. It's the only reason I trust my own data now, and when you get down to it, that's the entire point of buying research material at all.

— Jordan Feldman, Boston, MA

Frequently asked questions

What is a certificate of analysis (COA)?: A COA is a lab document reporting the measured identity and purity of a specific production lot: mass by HPLC, identity by mass spectrometry, and a measured purity percentage. A valid COA is tied to a specific lot number, not a generic catalog spec sheet.
Why isn't a supplier's own COA enough?: A manufacturer's COA is a starting point, not a verdict. We re-run identity and purity at an independent lab, not the one the manufacturer uses, because self-reported numbers can't be audited on their own. Only independent retesting confirms the label matches the vial.
What does "99% purity" actually tell you?: Less than it seems, on its own. A 99% purity figure is only meaningful if the remaining 1% is characterized. If that fraction is an unidentified compound the supplier can't account for, the number is close to meaningless. The impurity profile matters as much as the headline percentage.
Why is the cheapest peptide source usually the wrong one?: The cost of independent testing across multiple lots is real, and suppliers who skip it can price lower. Spot-buying the cheapest source means inheriting that skipped verification. Consistent label-to-vial accuracy costs money to guarantee.
How many tests does a manufacturer have to pass?: We require two independent test rounds across two separate lots before a manufacturer joins our active list, verifying that quality is repeatable and not a one-batch fluke.

Glossary

Certificate of Analysis (COA): A lab document reporting the measured identity and purity of a specific production lot.
HPLC: High-performance liquid chromatography: separates and quantifies the main compound and its impurities to measure purity.
Mass spectrometry: An analytical method that confirms molecular identity by measuring mass-to-charge ratio.
Impurity profile: The characterization of the non-target fraction of a sample: what the impurities actually are, not just how much.
Lot / batch: A single production run. Batch-specific documentation and testing is what ties quality claims to the vial you receive.

References

United States Pharmacopeia (USP). General Chapter <621> Chromatography — HPLC purity determination methods.
ICH Q3A(R2). Impurities in New Drug Substances — International Council for Harmonisation guideline on characterizing and reporting impurities.
Made in USA / independent third-party testing — see the batch-matched certificates of analysis provided with every Modern Bio peptide.

For research and educational purposes only. Not medical advice. Our compounds are supplied for academic and pre-clinical study and are not approved for human use.